Eyes on Pfizer ahead of update on Duchenne gene therapy
DMD gene therapy players may see some volatility this morning when Pfizer (NYSE:PFE) presents updated data this morning on DMD gene therapy candidate PF-06939926 at the Parent Project Muscular Dystrophy Annual Conference in Orlando, FL.
Gene therapy competitors Sarepta Therapeutics (NASDAQ:SRPT) (up a fraction) and Solid Biosciences (NASDAQ:SLDB) (+11%) are already on the move.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.